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While traditional cytotoxic drugs have shown limited efficacy in neuroendocrine tumors (NETs), their 
biological features have been characterized and can be exploited therapeutically. Their most prominent 
trait is an extraordinary vascularization in low-grade NETs and an hypoxia-dependent angiogenesis in 
high-grade NETs, which is associated to a significant expression of many pro-angiogenic molecules. 
Therefore, several antiangiogenic compounds have been tested in these malignancies and among these, 
sunitinib has demonstrated activity in pancreatic NET patients by dually targeting the VEGFR and 
PDGFR pathways. In spite of these efficacious clinical results, apparent resistance to antiangiogenic 
therapies has been described in NETs animal models and in clinical trials. Therefore, overcoming anti-
angiogenic resistance is a crucial step in the subsequent development of antiangiogenic therapies. Several 
strategies have been postulated to fight resistance, but pre-clinical studies and clinical trials will 
investigate and address these therapeutic approaches in the coming years in order to overcome resistance 
anti-angiogenic therapies in NETs. 
 





NETs are rare malignacies but their incidence and prevalence has increased in the last decades [1]. 
NETs comprise a heterogeneous family of tumors with a wide and complex spectrum of clinical behavior. 
The limited effectiveness of traditional DNA-damaging agents has led to the exploration of new targeted 
drugs based in the molecular features of these tumors, in order to improve their systemic treatment.  
NETs have a number of biological features that can be exploited therapeutically, such as an 
extraordinary tumor vascularization with high expression of several proangiogenic molecules [2,3]. 
Indeed, most NETs are hypervascular, as it is characteristic of normal endocrine glands which have a 
dense vascular network that facilitates hormone secretion and dumping to the bloodstream. Specifically, 
NETs show a microvascular density ranging from 10 to 20 fold higher than in typical carcinomas. 
However, many studies have shown that in  pancreatic NETs microvascular density is higher in benign, 
low-grade tumors than in malignant, high-grade tumors [4]. Furthermore, these studies have demonstrated 
that intratumor vessel density is associated with a good prognosis and prolonged survival [5], which is 
completely the opposite to other digestive epithelial tumors and most carcinomas in general. Thus, an 
intriguing characteristic of NETs is their physiologically derived high vessel density in low-grade tumors 
that is diminished over tumor progression and aggressiveness. Nevertheless, high-grade NETs typically 
show hypoxic areas and upregulation of hypoxia-response transcription factors (HIFs) and hypoxia-
dependent genes (Carbonic Anhydrase, Glucose Transporters…) [6]. Thus, while vessel density is lower 
in high-grade NETs, they show a very robust pro-angiogenic response that is clearly observed by 
increased endothelial proliferation and vascular overgrowth. 
The high vascularization of NETs has its molecular base on the specific repertoire of secreted 
molecules from neuroendocrine cells. Indeed, neuroendocrine cells physiologically express a high level of 
pro-angiogenic molecules, particularly in the pancreas, but also in peptidergic endocrine cells which 
constitutively synthesize several members of the VEGF family [7]. Consistently, NETs also typically 
express a variety of pro-angiogenic cytokines and growth factors, including vascular endothelial growth 
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factor (VEGF-A, VEGF-C), Fibroblast Growth Factors (FGF2…) amongst others. For example, 
neuroendocrine tumors and their derived cell lines demonstrate a high capacity to synthesize and secrete 
high levels of several VEGF family members [2].  
Overall, NETs not only show a dense vascular structure, but also have an angiogenic capacity that is 
characteristic of vessel-dependent tumors and thus evidencing a strong rationale for the use of anti-
angiogenic therapies in this type of malignancies. Therefore, several antiangiogenic compounds are 
currently undergoing clinical evaluation in NETs, either as monotherapy or in combination with 
chemotherapy or other targeted drugs. We will mention the biology of each of this mechanisms of 
angiogenesis and discuss the clinical data that is available to date. 
 
Early days, “Early” Anti-angiogenic Drugs 
Experimental evidence of the sensitivity of NETs to anti-angiogenic drugs is based on preclinical 
studies in animal models, where promising results were described in the mid and late 90-ties with 
strikingly efficacious effects ranging from tumor stabilization to tumor regression depending on the 
model used [8]. In particular, several antiangiogenic drugs have been evaluated in a transgenic mouse 
model of insulinoma, the RIP-Tag2, developed by Douglas Hanahan [9]. Early studies with the 
aminopeptidase inhibitor TNP-470, minocycline and interferon α/β demonstrated an antiangiogenic effect 
together with an effective tumor growth impairment [10]. Further studies utilized the naturally occurring 
antiangiogenic molecules angiostatin and endostatin which demonstrated both antiangiogenic and 
antitumoral effects in different stages of islet cell tumor progression [8].  
These preclinical results are associated to the clinical use of Thalidomide in NETs. Thalidomide is an 
orally bioavailable immunomodulatory drug with antiangiogenic properties due to its capacity to inhibit 
tumor necrosis factor alpha (TNF-α) production and also VEGF and basic fibroblast growth factor 
(bFGF) pathways. The first small clinical study (n=18) in NETs with thalidomide in monotheray didn’t 
show objective responses [11]. Nevertheless, the combination of thalidomide and temozolomide was 
evaluated in another phase II study with a  radiological response rate of 45% in pancreatic NETs and 7% 
in carcinoid tumors, respectively. However, a high incidence of grade 3-4 of lymphopenia was reported 
and 10% of the patients had opportunistic infections [12]. 
The use of Endostatin in the clinic has also demonstrated some benefit. Endostatin is a 20-kDa 
proteolytic fragment of collagen XVIII with antiangiogenic and antitumor activity in preclinical studies. 
The anti-angiogenic function of endostatin has been well documented during the past decade. However, 
the exact mechanism that endostatin executes its anti-angiogenic functions remains elusive. Both 
preclinical and human phase I studies of recombinant human endostatin (rhEndostatin) indicated activity 
in NETs. However, the phase II study performed in 40 patients with advanced NETs showed a high rate 
of stable disease (80%) but did not result in significant tumor regression. The toxicity was minimal[13]. 
 
The VEGF- VEGFR axis 
The key mediator of angiogenesis is the VEGF and VEGF signaling inhibition has been shown to 
result in significant tumor growth delay in a wide range of animal models [14]. Consistently, several 
antiangiogenic therapies targeting the VEGF-VEGFR2/KDR signaling axis have shown to be effective in 
mouse models of NETs. In particular, a monoclonal antibody that blocks VEGF-A ligand (AF-493-NA) 
and a blocking antibody of the VEGFR2 (DC101) have been tested in the RIP-Tag2 mouse model of 
insulinoma with consistent antiangiogenic effects in microvessel density, endothelial cell proliferation 
and antitumor activity with increased apoptosis [3, Sennino and McDonald, personal comunication]. 
Bevacizumab, a humanized monoclonal antibody that recognizes and blocks VEGF, failed to inhibit 
growth NETs cells in vitro, but reduced their angiogenic potential by blocking the cells’ ability to 
stimulate endothelial cell tube formation and proliferation and impaired tumor growth in animals [15]. 
Clinically, the activity of bevacizumab in NETs was tested in a randomized phase II study [16]. 
Forty-four patients on stable doses of octreotide were randomly assigned to 18 weeks of treatment with 
bevacizumab or PEG interferon alfa-2b. At disease progression (PD) or at the end of 18 weeks 
(whichever occurred earlier), patients received bevacizumab plus PEG interferon until progression. In the 
bevacizumab arm, four patients (18%) achieved confirmed partial response (PR), 17 patients (77%) had 
stable disease (SD), and one patient (5%) had PD. No objectives responses were observed in PEG 
interferon arm. Progression-free survival (PFS) rates after 18 weeks of monotherapy were 95% in 
bevacizumab arm versus 68% on the PEG interferon arm. Bevacizumab therapy also resulted in a 
significant reduction of tumor blood flow measured by functional CT scans.  
A larger randomized phase III in patients with unresectable metastatic or locally advanced carcinoid 
tumors comparing depot octreotide acetate and interferon alfa-2b versus depot octreotide acetate and 
bevacizumab is being conducted since 2007 (SWOG S0518, clinicaltrials.gov NCT00569127). The 
results of this study are awaited in the near future. 
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Bevacizumab has also been tested in combination with cytotoxic drugs. Kulke and cols explored the 
efficacy and safety of the combination of bevacizumab plus temozolomide in a small phase II trial [17]. 
The combination showed an objective response rate of 24% in pancreatic NETs but 0% in carcinoid 
tumors. A phase II study of capecitabine, oxaliplatin and bevacizumab for metastatic or unresectable 
neuroendocrine tumors were reported in 2010 ASCO Annual Meeting. PR were observed in 7 pts (23%), 
SD in 22 pts (71%), and PD in 2 pts (6%). Of the patients who achieved a PR, 6 had pancreatic NETs 
[18]. The combination with FOLFOX (oxaliplatin, leucovorin and 5-fluorouracil) has also been tested 
with similar results [19]. Further phase III trials are warranted to establish the efficacy of adding 
bevacizumab to chemotherapy in NETs. 
 
Other vascular players: PDGFR axis and the pericytes 
Another critical cellular component of the blood vessels, the perivascular cells or pericytes, have 
shown to be relevant targets for effective anti-angiogenesis. These cells mediate the stabilization of the 
vessels based on synthesis of new basement membrane and tight association of endothelial and pericyte 
junctions. Molecularly, a specific crosstalk between endothelial cells and pericytes that implicates VEGF 
and PDGF is key for the vascular formation and maintenance, and creates a crucial therapeutic 
opportunity that has been exploited [20]. For its supportive cooperative function aiding the endothelial 
cell stabilization and function, PDGFR inhibition has been developed in the context of dual inhibition of 
VEGFR and PDGFR [8]. Indeed, experimental studies with the RIP-Tag2 transgenic mouse model 
demonstrate a significant synergy when both endothelial cells and pericytes are dually blocked with 
VEGFR and PDGFR small molecule inhibitors such as Sunitinib [21,22]. 
On the clinical side, PDGFRs have been characterised in human pancreatic NET samples. PDGFR-α 
and PDGFR-β are commonly expressed both on tumor cells and tumor stroma [23]. The clinical approach 
to dually inhibit both VEGFR and PDGFR in NETs has been developed using several small molecule 
compounds such as sunitinib, sorafenib, vatalanib and pazopanib.   
Sunitinib is the only antiangiogenic drug tested in a randomized phase III placebo-controlled trial 
[24] in patients with progressive well differentiated pancreatic NETs which is stadistically positive in 
progression-free survival (11.4 months in sunitinib arm vs 5.5 months in placebo arm). Sunitinib 37.5 
mg/day was administered orally in a continuous schedule. The objective response rate was 9.3% in the 
sunitinib group versus 0% in the placebo group. This study was the first positive phase III trial with anti-
angiogenic drugs in the field and has changed the daily clinical practice in NETs. In a previous phase II 
study 107 patients (41 carcinoid tumors and 66 pancreatic NETs) with documented disease progression 
were treated with repeated six-week cycles of sunitinib 50 mg/day, four weeks on and two weeks off. The 
overall objective response rate was 16.7% in pancreatic NETs and 2.4% in carcinoid tumors [25].  
Sorafenib  is an orally active, multikinase inhibitor with selectivity for the VEGFR-2, VEGFR-
3,PDGFR-β , FLT3, c-kit, RET and RAF kinases. Sorafenib monotheraphy has been evaluated in a phase 
II trial in 93 patients with NETs. The overall response rate was 10% in both pancreatic and carcinoid 
NETs [26].  
Vatalanib inhibits all known VEGFRs, with particular selectivity for VEGFR-2. At higher 
concentrations vatalanib also inhibits PDGFR- β  and c-kit. Two phase II studies were reported in 2008 in 
NETs but both showed no significant radiological responses [27,28]. Finally, pazopanib, another potent 
inhibitor of VEGFR, PDFGR-α/β and c-kit, has been tested in combination with octeotride LAR in 
pancreatic NETs with 17% of PR and a PFS of 11.7 months [29]. 
 
Indirect anti-angiogenic mechanisms 
Certain anti-angiogenic drugs operate by targeting a tumor cell capacity of production of a particular 
pro-angiogenic growth factor. Such angiogenesis inhibitors have been termed "indirect anti-angiogenic 
inhibitors" as they do not target the effectors of angiogenesis (direct anti-angiogenic inhibitors), but rather 
indirectly regulate the pro-angiogenic capacities of the tumor cells. The most relevant of these indirect 
anti-angiogenic therapies in NETs is the inhibition of phosphatidylinositol 3-kinase (PI3K)-AKT-
mammalian target of rapamycin (mTOR) pathway, which is clearly activated in NETs [30]. 
The PI3K/AKT/mTOR pathway is activated in the majority of human cancers and this pathway is 
known to play a key role in numerous cellular functions, additionally to angiogenesis, which include 
proliferation, adhesion, migration, invasion, metabolism and survival. Activation of the PI3K/AKT 
pathway in tumor cells is a prominent enhancer of VEGF secretion but also modulates the expression of 
other angiogenic factors such as nitric oxide and angiopoietins. Numerous inhibitors targeting the 
PI3K/AKT/mTOR pathway have shown to decrease VEGF secretion and angiogenesis [31]. Among 
these, everolimus has demonstrated antiproliferative activity in several mammalian cell lines and 
clinically, this drug is the second targeted therapy in the field, besides sunitinib, that has shown efficacy 
and has become practice changing in the management of patients with progressive advanced pancreatic 
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NETs.(ENETS guidelines paper number 6 Pavel et al Neuroendocrinology In Press) The results of the 
randomized phase III placebo-controlled trial of everolimus in this population showed a median 
progression-free survival of 11.0 months with everolimus as compared with 4.6 months with placebo 
(p<0.001), representing a 65% reduction in the estimated risk of progression or death. Everolimus also 
showed a good tolerance with a low rate of severe adverse events [33]. 
 
Antiangiogenic Resistance 
Clinical results using anti-angiogenic drugs demonstrate only moderate gains in time to progression, 
and scarce benefits in overall survival, despite the long-term treatment. Why are there such modest and 
short-lasted benefits of anti-angiogenic therapies in the clinic? The initial hypothesis was that anti-
angiogenesis therapy would not induce resistance (“resistant to resistance”) because it targeted  
endothelial cells instead of the tumor cell itself [34]. Nevertheless, clinical and experimental evidence 
indicates that resistance to anti-angiogenic therapy does indeed occur. VEGF inhibition produces vascular 
triming and hypoxia, which leads to upregulation of multiple proangiogenic molecules, including VEGFs, 
FGFs and angiopoietins, which can contribute to eventual resistance [3, 35]. Furthermore, studies in the 
RIP-Tag2 model have described progression of NETs in course of anti-angiogenic therapies targeting the 
VEGF/VEGFR signaling axis. Thus, potent angiogenesis inhibition can alter the natural history of tumors 
by trigering resistance to therapy and increasing invasion and lymphatic or distant metastasis [36]. 
Strategies to overcome this resistance mechanism are warranted. Yao and Phan [37] have proposed 
some stratagies to overcome the anti-angiogenic resistance that are based in preclinical studies. Dual 
targeted therapies have been tested in xenografts. The combination of bevacizumab and HIF-1 or Sp1 
inhibitors may increase the therapeutic efficacy of anti-angiogenic treatment  [38, 39]. In another study, 
Allen and cols [40] suggest that cotargeting of VEGF and FGF signaling pathways can improve efficacy 
and overcome adaptive resistance to VEGF inhibition in the RIP-Tag2 model of pancreatic NETs. They 
tested the dual FGFR/VEGFR tyrosine kinase inhibitor brivanib in both first and second line following 
the failure of anti-VEGFR2 antibody (DC101) or sorafenib showing promising results in overcoming 
resistance to VEGF-selective therapy. 
On the clinical side, some phase II studies have tested the combination of antiangiogenic drugs. 2-
methoxyestradiol (2ME2) administered in combination with bevacizumab has been evaluated in a 
prospective study in thirty-one patients with metastatic carcinoid tumors [41]. No confirmed radiologic 
responses by RECIST were observed. However, 68% of the radiologically evaluable patients experienced 
at least some degree of tumor reduction, and the median PFS time was 11.3 months. The results of a study 
[42] with the combination of sorafenib and bevacizumab were reported in 2011 ASCO Annual meetitng. 
The overall response ratio was 9.8% and the disease control rate at 6 months was 95.1%. Median 
progression free survival was 12.4 months. The most common grade 3-4 toxicities were hand-foot 
syndrome and asthenia which occurred in 20.5% and 15.9% of patients, respectively. Another trial have 
tested the combination of Bevacizumab and Everolimus in NETs. Addition of Everolimus to 
Bevacizumab was associated with further decrease in tumor blood flow (15%; p=0.02) than Bevacizumab 
alone. By intention to treat (ITT) analyses, there were 26% of PR  and 27% of SD. The median PFS was 
14.4 months [43].  
On the other hand, the identification of biomarkers for response or resistance to a particular anti-
angiogenic regimen is imperative. A study in the RIP-Tag2 model of pancreatic NETs described that 
tumors refractory to therapy following long-term treatment with a vascular endothelial growth factor 
receptor-2 blocking antibody contained blood vessels with a prolific investment of pericytes expressing α-
smooth muscle actin. Further studies are warranted to validate the occurrence of pericytes expressing α-
smooth muscle actin as a biomarker for tumors refractory to therapy [44]. 
 
A perspective 
Morphological, histological and molecular features of NETs strongly support the notion that 
angiogenesis is a promising target in these malignancies. Indeed, several anti-angiogenic drugs have been 
clinically validated and two of those have been recently approved and are being incorporated in the daily 
clinical practice of pancreatic NETs. Nevertheless, not all patients respond to these therapies 
demonstrating upfront refractoriness to therapy or intrinsic resistance. This patient population has to be 
carefully studied and detected in the future to find the most appropriate patient selection marker or 
charateristic in order to effectively treat these refractory patients. On the other hand, anti-angiogenic 
drugs demonstrate clinical efficacy in many NETs patients, but these clinical benefits are overshadowed 
by apparent acquired resistance to antiangiogenic therapies emerging in NETs. Therefore, overcoming 
antiangiogenic resistance is a crucial step in the future development of antiangiogenic therapies. Several 
strategies have been postulated to fight resistance, including multi-pathway inhibitors or multi-
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combination of anti-angiogenic drugs that target different pathways that can revert resistance. In this 
sense, clinical studies that investigate and address these approaches in the coming years are warranted. 
Neverhteless, preclinical data in the RIP-Tag2 model indicates that many of these mechanisms of 
resistance show reversibility after anti-angiogenic therapy has been stopped (Pàez-Ribes & Casanovas, 
unpublished observations). This confirms that these forms of resistance may reflect adaptations to therapy 
rather than irreversively acquired capabilities, and thus suggest that swithching to a non-angiogenic drug 
in these resistant patients could revert their angiogenesis dependance and re-sensitize these patients to 
anti-angiogenic drugs. Following this hypothesis, sequential treatment with an anti-angiogenic drug 
followed by a non-anti-angiogenic drug (i.e. another targeted therapy or chemotherapy) could resensitize 
patients to another anti-angiogenic drug as a third line of treatment. Obviously, many studies are 
warranted to unravel the preclinical basis and clinical potential of this hypothetical sequential treatment 
and to finally determine its clinical benefit for NETs patients.  
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